Company Profile

Forum Pharmaceuticals Inc (AKA: EnVivo Pharmaceuticals Inc)
Profile last edited on: 4/5/19      CAGE:       UEI:

Business Identifier: Small-molecule therapeutics for disorders of the central nervous system (CNS)
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

225 Second Avenue
Waltham, MA 02451
   (617) 225-4250
Location: Multiple
Congr. District: 05
County: Middlesex

Public Profile

With facilities in MA and in CA, EnVivo Pharmaceuticals Inc had been named one of the "Fierce 15" Leading Biotech Companies and drew a management team from the full complement of lead players in the bio tech space. Committed to the discovery and long-term development of innovative drugs that would improve function and change the course of disease in patients with dementias, schizophrenia and other neuropsychiatric disorders, the approach was multi-target and multi-program by design. EnVivo built a robust and diverse pipeline focused on important neuropsychiatric conditions for which currently available therapies are insufficient and leave profound unmet needs. Renamed Forum Pharmaceuticals somewhere along the way, the firm was well financed - the primary investor was Fidelity Biosciences, now called F-Prime Capital reported as pouring hundreds of millions of dollars into the company over the years and becaming Forum’s sole owner in 2008 - and with a highly experienced team, the firm was strongly positioned to develop and commercialize their own programs. In fact, in light of the failure of two of the firm's lead products in clinical trials in June 2016, FORUM Pharma closes Its door

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2002 1 NIH $132,621
Project Title: A new method of drug discovery for CNS diseases

Key People / Management

  Deborah Dunsire -- CEO

  Deborah Dunsire -- President and CEO

  Christopher L Burnley -- Chief Business Officer

  Christine Carberry -- Former VP Program & Alliance Management

  Zach W Hall

  Gerhard Koenig -- Chief Scientific Officer

  Jean-Marie Vallet -- Vice President, Business Development